Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 3 | 3 |
| 2024 | 0 | 5 | 5 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Arctigenin Suppresses Breast Cancer Growth In Vitro and In Vivo Through Subtype-Specific Multi-Targeting Activity. Int J Mol Sci. 2026 Jun 03; 27(11).
-
A Cyanobacteria-Derived RNA Aptamer Resensitizes Prostate Cancer to Hormone Therapy. Cancer Res. 2025 Jul 15; 85(14):2714-2725.
-
Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells. Drug Resist Updat. 2025 Mar; 79:101196.
-
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth. J Immunother Cancer. 2024 Dec 22; 12(12).
-
Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models. Nutrients. 2024 Jul 22; 16(14).
-
In Vivo Effects of Bay 11-7082 on Fibroid Growth and Gene Expression: A Preclinical Study. Cells. 2024 Jun 24; 13(13).
-
Targeting the long non-coding RNA MIAT for the treatment of fibroids in an animal model. Clin Sci (Lond). 2024 Jun 19; 138(12):699-709.
-
89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors. Mol Cancer Ther. 2024 Jun 04; 23(6):890-903.
-
Reciprocal Regulation Between Forkhead Box M1/NF-?B and Methionine Adenosyltransferase 1A Drives Liver Cancer. Hepatology. 2020 11; 72(5):1682-1700.
-
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695.